PURPOSE: To study the catecholamine-releasing effect of peripheral intravenous administration of the nonionic contrast medium iohexol in patients with pheochromocytomas. MATERIALS AND METHODS: Ten patients (eight women, two men; mean age, 44 years; age range, 25-70 years) with pheochromocytomas and related tumors and six healthy volunteers (five men, one woman; mean age, 31 years; age range, 27-35 years) were examined. Plasma catecholamine levels were measured at intervals for 60 minutes after the injection of 0.9% saline or iohexol on 2 separate days. All 10 patients intravenously received the specific alpha-adrenergic blocker phenoxybenzamine hydrochloride (0.5 mg/kg in 250 mL of 5% dextrose infused over 2 hours) 24 hours before iohexol-enhanced computed tomography. RESULTS: There was no statistically significant increase in epinephrine or norepinephrine levels in the patients or the control subjects. CONCLUSION: While it may be prudent to administer oral alpha- and beta-adrenoceptor antagonists in all patients with a biochemically proved pheochromocytoma to control their symptoms and to prevent a spontaneous adrenergic crisis, specific blockade may not be required before contrast medium-enhanced scanning with iohexol. Although the sample size of this study is relatively small, the results do suggest that in an incidentally detected, clinically silent adrenal mass that may or may not be hypersecreting, the nonionic contrast medium iohexol may be used for scanning without blockade.
PURPOSE: To study the catecholamine-releasing effect of peripheral intravenous administration of the nonionic contrast medium iohexol in patients with pheochromocytomas. MATERIALS AND METHODS: Ten patients (eight women, two men; mean age, 44 years; age range, 25-70 years) with pheochromocytomas and related tumors and six healthy volunteers (five men, one woman; mean age, 31 years; age range, 27-35 years) were examined. Plasma catecholamine levels were measured at intervals for 60 minutes after the injection of 0.9% saline or iohexol on 2 separate days. All 10 patients intravenously received the specific alpha-adrenergic blocker phenoxybenzamine hydrochloride (0.5 mg/kg in 250 mL of 5% dextrose infused over 2 hours) 24 hours before iohexol-enhanced computed tomography. RESULTS: There was no statistically significant increase in epinephrine or norepinephrine levels in the patients or the control subjects. CONCLUSION: While it may be prudent to administer oral alpha- and beta-adrenoceptor antagonists in all patients with a biochemically proved pheochromocytoma to control their symptoms and to prevent a spontaneous adrenergic crisis, specific blockade may not be required before contrast medium-enhanced scanning with iohexol. Although the sample size of this study is relatively small, the results do suggest that in an incidentally detected, clinically silent adrenal mass that may or may not be hypersecreting, the nonionic contrast medium iohexol may be used for scanning without blockade.
Authors: Frederieke M Brouwers; Jacques W M Lenders; Graeme Eisenhofer; Karel Pacak Journal: Rev Endocr Metab Disord Date: 2003-05 Impact factor: 6.514
Authors: Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: F Ofei; R Darko; J Appiah-Kusi; H Aduful; H Baddoo; Y Adu-Gyamfi; Y Tettey; Rk Gyasi; L Aleksenko; Ed Yeboah; Eq Arc-Hampong; Aa Yeboah; E Ogoe Journal: Ghana Med J Date: 2007-06
Authors: Smita K Baid; Edwin W Lai; Robert A Wesley; Alex Ling; Henri J L M Timmers; Karen T Adams; Anna Kozupa; Karel Pacak Journal: Ann Intern Med Date: 2009-01-06 Impact factor: 25.391